Clinical Psychopharmacology · Paper A
Ketamine and esketamine
Ketamine and esketamine matter because they act within hours rather than the weeks typical antidepressants take, offering a fast option for treatment-resistant depression (depression that has not responded to at least two adequate antidepressant trials). Both are NMDA (N-methyl-D-aspartate) receptor antagonistsA drug that blocks a receptor, stopping it from being activated.Read more →, meaning they block a glutamate receptor rather than working through serotonin or noradrenaline like most antidepressants. For example, imagine a patient with severe depression and active suicidal thoughts who cannot wait the usual four to six weeks for an SSRISelective serotonin reuptake inhibitor, a common type of antidepressant.Read more → to work: ketamine can lift mood within hours. This speed comes from a different, glutamate-based mechanism rather than the monoamine systems older antidepressants target.
By blocking NMDA glutamate receptors, ketamine triggers downstream changes that rapidly strengthen synaptic connections, producing an antidepressant effect within hours that can last days. Esketamine, the S-enantiomer of ketamine, is delivered as a nasal spray and is licensed specifically for treatment-resistant depression, given alongside an oral antidepressant under supervision. Both drugs commonly cause dissociationA disconnection between a person's thoughts, feelings, memories, or sense of identity, often as a response to stress.Read more → (a feeling of detachment from one's body or surroundings) during administration, which is why dosing happens in a monitored clinical setting. Say a patient feels detached and dreamlike for an hour after a dose: this is expected dissociation, not a sign of harm, and it resolves quickly. In practice, clinicians also watch for abuse potential and, with repeated recreational use, ketamine-induced cystitis (painful bladder inflammation).